FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
106 letters match. Newest first.
-
DrugsRonanRx, Inc. dba RonanRx
FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsLovelace Biomedical Research Institute
Lovelace Biomedical's quality unit failed to ensure final drug study reports matched raw data, FDA says.
Medium -
DrugsOnline Generic Medicine/www.onlinegenericmedicine.com
FDA warned Online Generic Medicine that its website sells unapproved, misbranded injectable semaglutide to U.S. consumers.
High risk -
FoodBioDrive, Inc.
FDA warned BioDrive that its Evolv GLP-1 Biomimetic dietary supplement is adulterated over the new dietary ingredient EV1-Peptide and safety concerns.
High risk -
DrugsPeak Performance Peptides
Peak Performance Peptides sold unapproved injectable peptide drugs, including semaglutide and retatrutide, without FDA approval.
High risk -
DrugsNuScience Peptides LLC
FDA warned NuScience Peptides that it sells unapproved injectable peptide drugs, including GLP-1 and tesamorelin products, on its website.
High risk -
DrugsPeptide Partners LLC
Peptide Partners LLC sold seven unapproved injectable peptide drugs online with disease-treatment claims, FDA says.
High risk -
DrugsTXP Innovations LLC dba Tex Peptides
FDA warned Dallas peptide seller TXP Innovations (Tex Peptides) that its website sells unapproved injectable drugs, including semaglutide and tirzepatide.
High risk -
DrugsNativeMed LLC dba NativeMed
FDA warned telehealth seller NativeMed that its website misbranded compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsFitRX, LLC dba AM RX
FDA warned telehealth seller AM RX that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
Medium -
DrugsAltru Telehealth, LLC dba Altru Telehealth
FDA warns Altru Telehealth that its website falsely claimed compounded semaglutide/tirzepatide and compounding pharmacies were FDA-approved.
Low -
DrugsTrinity HealthCare Supply, LLC dba altRx
FDA warns altRx over misleading website claims for compounded semaglutide and tirzepatide, including 'clinically proven' and wrong compounder label.
Low -
DrugsAmie Health, Inc. dba Amie
FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
Medium -
DrugsThrivelab Co. dba Thrivelab
FDA warned telehealth seller Thrivelab that its website misbrands compounded semaglutide with false claims suggesting FDA approval.
Medium -
DrugsPublic Health Solution LLC dba DrMedHealth
FDA warned DrMedHealth over false website claims that compounded semaglutide and tirzepatide have the same active ingredient as Ozempic and Mounjaro.
Low -
DrugsD&H Medical Services
FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.
Low -
DrugsMomentum Health 360 dba Momentum Health
FDA warned Momentum Health over false claims for compounded semaglutide, tirzepatide, and liraglutide.
Low -
DrugsFITISH
FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.
Low -
DrugsJoi and Blokes dba Joi + Blokes
FDA warned telehealth seller Joi + Blokes that its website misbrands compounded semaglutide and tirzepatide with false, misleading claims.
Medium -
DrugsClover Meds LLC dba Clover Meds
Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.
Medium -
DrugsHealthPartners Neuroscience Center Research and Innovation
FDA warned HealthPartners Neuroscience Center that its animal studies of an investigational drug violated good laboratory practice rules.
Medium -
DrugsHarbin Jixianglong Biotech Co., Ltd.
FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.
High risk -
DrugsNew Life Pharma LLC
New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.
High risk -
DrugsLovega LLC dba Pink Pony Peptides
FDA warned Pink Pony Peptides that its GLP-2 TZ, GLP-3 RT and Bacteriostatic Water are unapproved new drugs sold online.
High risk -
DrugsGuangzhou Huli Technology Co., Ltd. dba Fantasy Face
FDA warned Guangzhou Huli Technology (dba Fantasy Face) for selling an unapproved GLP-1 weight loss drug online.
Medium -
DrugsGram Peptides
Gram Peptides sold unapproved injectable peptide drugs and bacteriostatic water online as new drugs, FDA says.
High risk -
DrugsPrime Sciences
Prime Sciences sells injectable peptide drugs and BAC water online without FDA approval, FDA says.
High risk -
DrugsMile High Compounds LLC
FDA warned Mile High Compounds that it sells unapproved injectable GLP-1-like drugs and BAC water online.
High risk -
DrugsPekCura Labs
FDA warned PekCura Labs that its GLP-1-S, GLP-2-T, GLP-3-R, and bacteriostatic water products are unapproved new drugs sold online.
High risk -
DrugsVedic Lifesciences Pvt. Ltd.
FDA warns Vedic Lifesciences over false final reports for three nonclinical drug studies.
Medium -
DrugsPremium Health Management Inc. dba Premium Health
FDA warns Premium Health over misleading website claims for compounded semaglutide and tirzepatide.
Low -
DrugsZeuss LLC dba Zeuss
FDA warned telehealth seller Zeuss that its website misbrands compounded tirzepatide by implying Zeuss makes it and that it is FDA-approved.
Medium -
DrugsLean Rx, Inc. dba SkinnyRx
SkinnyRx's website misbranded compounded semaglutide and tirzepatide by wrongly suggesting it makes the drugs and that they are FDA-approved.
Low -
DrugsKare Solutions, LLC dba Zappy
FDA warned Zappy that its website falsely suggested it compounds semaglutide, tirzepatide, and liraglutide and made misleading approval-like claims.
Low -
DrugsStrut Health, LLC dba Strut
FDA says Strut Health's website falsely labeled compounded semaglutide and tirzepatide as its own and FDA-approved.
Low -
DrugsRefills Health, LLC dba Refills Health
FDA told telehealth seller Refills Health its website misbrands compounded semaglutide by implying FDA approval and naming itself as maker.
Medium -
DrugsWeightless Medical LLC dba WeightCare
FDA warned telehealth seller WeightCare that its website falsely presents it as the compounder of semaglutide and tirzepatide drugs.
Low -
DrugsViv Health, Inc. dba VIV RX
FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
Medium -
DrugsPharmaZee
FDA warns PharmaZee over misleading website claims for compounded semaglutide and tirzepatide, including implying PharmaZee compounds them and that they are proven.
Low -
DrugsGood Girl LLC dba GoodGirlRX
FDA warns telehealth seller GoodGirlRX that its website misbrands compounded semaglutide and tirzepatide, claiming FDA approval and implying it is the compounder.
Medium -
DrugsJoin Josie
FDA says Join Josie's website misbranded compounded semaglutide and tirzepatide by falsely implying FDA approval and naming Join Josie as compounder.
Low -
DrugsKin Meds
FDA warned Kin Meds over false claims for compounded semaglutide and tirzepatide, including implying it is the compounder and that products are approved.
Low -
DrugsLevity Inc. dba Levity
FDA warned Levity over misleading website claims for compounded semaglutide and liraglutide, including implying Levity made the drugs and that they were FDA-approved.
Low -
DrugsMaxLife Technologies Inc. dba Maxlife
FDA told telehealth seller Maxlife its website falsely implied Maxlife compounds semaglutide and tirzepatide and that the drugs are FDA-approved.
Medium -
DrugsBetter Health Labs, Inc. dba Measured
FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.
Medium -
DrugsMEDVi, LLC dba MEDVi
FDA says telehealth seller MEDVi misbranded compounded semaglutide and tirzepatide by implying MEDVi makes them and that they are FDA-approved.
Medium -
DrugsBelle Health LLC dba Belle
FDA warned Belle Health that its website falsely suggests Belle compounds semaglutide and tirzepatide, making the drugs misbranded.
Low -
DrugsDeluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics
FDA warned Deluxe IV and Aesthetics over misleading website claims for compounded semaglutide and tirzepatide, including implying FDA approval.
Low -
DrugsAspen Aesthetics dba Fifty 410
FDA warns Fifty 410 over misleading website claims for compounded semaglutide and tirzepatide, including implied compounding and 'clinically proven' claims.
Low -
DrugsFitRX, LLC dba FitRx
FitRx's website misbranded compounded semaglutide and tirzepatide with false and misleading claims, FDA says.
Medium